AR+ luminal cells form the bulk of the primary PCa tumor and require AR transcriptional activity for survival and proliferation [8]; thus, PCa therapies block androgen production (androgen deprivation therapy, ADT) or directly inhibit AR activity (anti-androgens) [8]. This evidence concerns the gene AR and neoplasm.